The Technical Analyst
Pyxis Oncology, Inc. [PYXS]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Pyxis Oncology, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-0.66% $4.50
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 261.60 mill |
| EPS: | -1.850 |
| P/E: | -2.43 |
| Earnings Date: | May 11, 2024 |
| SharesOutstanding: | 58.13 mill |
| Avg Daily Volume: | 0.914 mill |
| RATING 2024-04-23 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.43 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.41x |
| Company: PE -2.43 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.255 (-105.68%) $-4.76 |
| Date: 2024-04-23 |
| Expected Trading Range (DAY) |
|---|
|
$ 3.85 - 5.15 ( +/- 14.40%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-26 | Connealy Pamela Ann | Buy | 328 710 | Common Stock |
| 2024-03-26 | Sullivan Lara | Buy | 1 071 242 | Stock Option (Right to Buy) |
| 2024-03-26 | Flavin John L | Buy | 35 219 | Common Stock |
| 2024-03-26 | Cline Darren S | Buy | 35 219 | Common Stock |
| 2024-03-26 | Lewis-hall Freda C | Buy | 35 219 | Common Stock |
| INSIDER POWER |
|---|
| 77.59 |
| Last 91 transactions |
| Buy: 19 296 822 | Sell: 29 966 464 |
Forecast:
16:00 - $4.49
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $4.49
Forecast 2: 16:00 - $4.49
Forecast 3: 16:00 - $4.49
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.50 (-0.66% ) |
| Volume | 0.384 mill |
| Avg. Vol. | 0.914 mill |
| % of Avg. Vol | 41.99 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PYXS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $3.70 | N/A | Active |
|---|
PYXS
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2024-03-28 16:30:00 - Press Release
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Boston, march 28, 2024 (globe newswire) -- pyxis oncology, inc. (nasdaq: pyxs), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, reported today that pyxis oncology's compensation committee of the board of directors granted restricted stock units with respect to an aggregate of 39,680 shares of pyxis oncology's common stock and stock options to purchase an aggregate of 49,600 shares of pyxis oncology's common stock to a newly hired employee. the awards were granted under the pyxis oncology, inc. 2022 inducement plan with a grant date of march 28, 2024, as an inducement material to the new employee entering employment with pyxis oncology, in accordance with nasdaq listing rule 5635(c)(4).
2024-03-27 07:30:00 - Press Release
Pyxis Oncology Obtains $8 Million Payment For The Sale Of Royalty Rights
Non-dilutive funding to support development of first-in-concept lead antibody-drug conjugate (adc) asset, pyx-201 pyxis oncology retains rights to three other antibodies in development by apexigen's licensees discovered through the apximab platform boston, march 27, 2024 (globe newswire) -- pyxis oncology, inc. (nasdaq: pyxs), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that it has completed the sale of its rights to royalties from the commercialization of beovu ® (brolucizumab-dbll) and another asset to novartis for a one-time cash payment of $8 million. as part of pyxis oncology's acquisition of apexigen, inc...
2024-03-21 07:30:00 - Press Release
Pyxis Oncology Provides Corporate Update And Reports Financial Results For Fourth Quarter And Full Year 2023
Pyx-201 phase 1 part 1 trial progressing with initial data expected in the fall of 2024 pyx-106 phase 1 trial progressing with initial data expected 2h 2024 completed $50 million private placement expected cash runway into 2h 2026 boston, march 21, 2024 (globe newswire) -- pyxis oncology, inc. (nasdaq: pyxs), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the year and quarter ended december 31, 2023, and provided a corporate update. pyx-201, a first-in-concept tumor stroma targeting antibody-drug conjugate (adc) against the stromal extradomain-b fibronectin (edb+fn) target, has dosed 37 patients in 6 cohorts since initiating the phase 1 trial in march 2023.
2024-03-13 08:00:00 - Press Release
Pyxis Oncology Expands Board Of Directors With Appointment Of Santhosh Palani, Ph.d., Cfa
Boston, march 13, 2024 (globe newswire) -- pyxis oncology, inc. (nasdaq: “pyxs”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of santhosh palani, ph.d., cfa, to its board of directors, effective march 12, 2024.
2024-03-07 16:30:00 - Press Release
Pyxis Oncology To Present At Leerink Global Biopharma Conference 2024
Boston, march 07, 2024 (globe newswire) -- pyxis oncology, inc. (nasdaq: pyxs), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that lara s. sullivan, m.d., president and chief executive officer, will participate in a fireside chat on wednesday, march 13, 2024 at 8:40 am est at the leerink partners global biopharma conference, miami beach, florida, where members of management will also host investor one-on-one meetings.
Latest News
2024-04-12 10:56:12 - Zacks Investment Research
Does Pyxis Oncology (PYXS) Have the Potential to Rally 61.29% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 61.3% in Pyxis Oncology (PYXS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2024-03-27 13:07:58 - InvestorPlace
3 Biotech Stocks to Buy on the Dip: March 2024
One of the best dip-buying opportunities in biotech stocks to buy was in Viking Therapeutics (NASDAQ: VKTX ). After hitting a high of $99.41, VKTX dipped back to about $60.30.
2024-03-26 13:01:03 - Zacks Investment Research
All You Need to Know About Pyxis Oncology (PYXS) Rating Upgrade to Buy
Pyxis Oncology (PYXS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2024-03-19 14:58:39 - InvestorPlace
From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires
Given the current risk-on sentiment, it is perhaps an ideal time for investors to scoop up some of the top biotech stocks. The stock market is booming, and with investors looking to take on more risk, a potential surge in biotech stocks seems likely.
2024-03-07 16:30:00 - GlobeNewsWire
Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024
BOSTON, March 07, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Wednesday, March 13, 2024 at 8:40 AM EST at the Leerink Partners Global Biopharma Conference, Miami Beach, Florida, where members of management will also host investor one-on-one meetings.
2024-03-05 16:45:00 - GlobeNewsWire
Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting
PYX-201, an EDB+FN-specific tumor stroma-targeting ADC, demonstrates potent anti-tumor efficacy across multiple human cancers in PDX tumor models
2024-02-22 18:00:53 - InvestorPlace
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024
With new innovation, high demand for better treatment, pharmaceutical companies strengthening pipelines and a resurgence of mergers and acquisitions, biotech stocks could offer some of the most explosive opportunities of the year. “What's more, big pharmaceutical companies with sizable piles of cash and the need to address patent expirations on some top-selling products later this decade will be hunting for companies with innovative drugs in development,” says Morningstar.com.
2023-08-21 11:17:02 - Zacks Investment Research
Down -15.56% in 4 Weeks, Here's Why You Should You Buy the Dip in Pyxis Oncology, Inc. (PYXS)
Pyxis Oncology, Inc. (PYXS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
2023-08-01 16:01:00 - GlobeNewsWire
Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference
BOSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President and Chief Executive Officer, will present a company overview at the BTIG Virtual Biotechnology Conference on August 7, 2023 at 3:00 PM EST. The Pyxis Oncology management team will also host investor meetings that same day. To join the conference, email info@btig.com.
2023-07-17 13:32:36 - Zacks Investment Research
Pyxis Oncology, Inc. (PYXS) Upgraded to Strong Buy: What Does It Mean for the Stock?
Pyxis Oncology, Inc. (PYXS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.